|
DRUG RELEASING BALL vs. PHARMACOACTIVE STENT IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY) IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY)
RECRUITINGN/ASponsored by Fundación EPIC
Actively Recruiting
PhaseN/A
SponsorFundación EPIC
Started2024-10-23
Est. completion2026-05-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06448637
Summary
Randomized, controlled, open and multicenter study that analyzes the vasomotor function 8 months after use of the drug-eluting balloon (DCB) vs. drug-eluting stent (DES) in vessels ≥ 3.5 mm
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: Patients who meet all of the following conditions are included. * Patients aged ≥ 18 years and; * Patients with chronic coronary syndrome, acute coronary syndrome without ST segment elevation or acute coronary syndrome with elevation ST segment in non-culprit lesions 48 hours after the event and; * Patients with de novo lesions in vessels ≥ 3.5 mm without calcification significant no visible thrombus and; * Patients who have been informed of the characteristics of the study and have provided their written informed consent. Exclusion Criteria: Patients who meet at least one of the following conditions are excluded: * Patients with any contraindication for the administration of acetylcholine (ACh) or nitroglycerin (NTG). * Patients with a history of coronary vasospasm or spontaneous dissection of the coronary artery. * Patients with significant medical, surgical or psychiatric condition that would affect the safety of the subject or influence the outcome of the study according to the doctor's opinion. * Patients who received a combination of DES and DCB in the same vessel * Patients with glomerular filtration rate \<30 ml/min/ 1.73 m2 * Patients with body mass index \>35 (may affect the evaluation qualitative diameter of the coronary artery). * Patients with symptomatic congestive heart failure. * Patients with significant autoimmune inflammatory conditions and patients taking immunomodulatory medications (including methotrexate, cyclosporine, steroids). * Patients with heart transplant. * Patients with anemia (Hb \<12 g/dL in men and \<10 g/dL in women). * Patients, women of childbearing age with a positive pregnancy test. * Pregnant female patients. * Patients included in other clinical trials with active follow-up.
Conditions2
Coronary Artery DiseaseHeart Disease
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorFundación EPIC
Started2024-10-23
Est. completion2026-05-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06448637